A61P 7/04
Antihaemorrhagics
Official title: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
A61P7/04 (Antihaemorrhagics) appears on 4,910 US grants and 7,848 published applications in this corpus.
Search patents in A61P- Granted patents
- 4,910
- Published applications
- 7,848
- Assignees
- 2,373
- Inventors
- 12,168
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 4 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 7 | 0 |
| 1983 | 3 | 0 |
| 1984 | 5 | 0 |
| 1985 | 5 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 8 | 0 |
| 1989 | 16 | 0 |
| 1990 | 6 | 0 |
| 1991 | 5 | 0 |
| 1992 | 15 | 0 |
| 1993 | 9 | 0 |
| 1994 | 14 | 0 |
| 1995 | 16 | 0 |
| 1996 | 28 | 0 |
| 1997 | 30 | 0 |
| 1998 | 50 | 0 |
| 1999 | 56 | 0 |
| 2000 | 57 | 0 |
| 2001 | 70 | 31 |
| 2002 | 91 | 143 |
| 2003 | 90 | 266 |
| 2004 | 69 | 284 |
| 2005 | 88 | 284 |
| 2006 | 121 | 321 |
| 2007 | 118 | 323 |
| 2008 | 137 | 341 |
| 2009 | 150 | 466 |
| 2010 | 220 | 452 |
| 2011 | 241 | 467 |
| 2012 | 282 | 500 |
| 2013 | 313 | 416 |
| 2014 | 358 | 457 |
| 2015 | 311 | 414 |
| 2016 | 299 | 407 |
| 2017 | 241 | 316 |
| 2018 | 237 | 310 |
| 2019 | 213 | 325 |
| 2020 | 203 | 256 |
| 2021 | 188 | 232 |
| 2022 | 155 | 200 |
| 2023 | 104 | 186 |
| 2024 | 101 | 172 |
| 2025 | 106 | 164 |
| 2026 | 59 | 115 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds6 Oct 2026US 12,751,954 B2Principia Biopharma Inc.
- Compositions and methods for the treatment of hemophilia6 Oct 2026US 12,753,418 B2Poseida Therapeutics, Inc.
- Treating vasculature related diseases or disorders using nanoparticles29 Sep 2026US 12,746,212 B2The Regents of the University of California
- Methods for preparing liposomal formulations15 Sep 2026US 12,734,181 B2Jazz Pharmaceuticals Therapeutics, Inc.
- Plasmin inhibitor, preparation method therefor, and application thereof15 Sep 2026US 12,735,421 B2Scinnohub Pharmaceutical Co., Ltd
- Treatment of hemophilia with fitusiran1 Oct 2026US 2026/0294956 A1Genzyme Corporation
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
- Liver-specific regulatory nucleic acid sequences1 Oct 2026US 2026/0297615 A1Askbio Inc.
- Stat3 inhibitor to treat subarachnoid hemorrhage24 Sep 2026US 2026/0283999 A1
- Polymer-based hemostatic formulations provided with anti microbial, anti-viral and anti-inflammatory properties and production method thereof24 Sep 2026US 2026/0284134 A1
Most cited
By later US patents
- Nanostructure-enhanced platelet binding and hemostatic structures1,405US 8,319,002 B2Nanosys, Inc. · 2012
- Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue1,214US 6,458,147 B1NeoMend, Inc. · 2002
- Mesocellular oxide foams as hemostatic compositions and methods of use1,075US 8,202,549 B2The Regents of the University of California · 2012
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Modified peptides as therapeutic agents359US 6,660,843 B1Amgen Inc. · 2003